INTRODUCTION
============

Helium (He) was discovered in 1868 by the French astronomer Pierre-Jules-César Janssen.^([@r1],[@r2])^ In 1934, Barach described the first application of He for the treatment of airway obstruction and asthma exacerbations and demonstrated that its low density reduced the work of breathing and improved ventilation.^([@r3]-[@r5])^

Since that time, several mixtures of He and oxygen (so-called \"heliox\" - He/O~2~) have been used for the treatment of several respiratory problems, such as exacerbations of asthma and chronic bronchitis, i.e., obstructive diseases associated with increased expiratory resistance.^([@r1],[@r2],[@r5])^

He/O~2~ can be used with any oxygen delivery device, including nasal cannulas, face masks, noninvasive ventilation, and conventional mechanical ventilation devices.^([@r1],[@r4],[@r6])^

Some requirements are needed for heliox to be used during invasive mechanical ventilation, including the availability of a ventilator (e.g., the Maquet Servo-i) with a specific module for automatic recalibration of the replacement of air by He/O~2~ (supplied by pressurized bottles in a ratio of 80% He:20% O~2~ - [Figure 1](#f1){ref-type="fig"}). The fraction of inspired oxygen (FiO~2~) is titrated as a function of the oximetry target values. The effect of He/O~2~ on the ventilatory mechanics is inversely proportional to the FiO~2~ in the inspired gas mixture.

Figure 1Use of heliox (80:20) with a Maquet Servo-I ventilator.

Except for the Maquet Servo-i, volume readings are inaccurate on all ventilators because the flow meter is calibrated for air.^([@r1])^ Furthermore, the dosing of the amount of administered aerosols is also affected by the type of gas used. It should be noted that no adverse effects associated with the use of He/O~2~ have been described.^([@r4],[@r7])^ Therefore, administration of He/O~2~ is safe and does not require the use of any type of gas exhaustion system.

Literature review
-----------------

From the 1930s to the present time, several studies have evaluated the impact of He/O~2~ delivery on the maximum flow rate, airway peak pressure, dyspnea scores, and performance in pulmonary function tests. However, the data provided by such studies were often contradictory concerning the usefulness of He/O~2~ in pulmonary obstructive disease.^([@r1],[@r3])^

Colebourn et al *.*^([@r8])^ conducted a systematic review of all of the controlled randomized trials that compared He/O~2~ to air-oxygen mixtures in patients with acute exacerbations of asthma and chronic obstructive pulmonary disease. The primary outcome measures in the studies of asthma included changes in spirometric parameters, namely forced expiratory volume in one second, forced vital capacity, and forced expiratory flow; the secondary outcomes consisted of clinical (dyspnea score and respiratory rate) and analytical (arterial oxygen saturation) parameters and hospital admission rate. The results did not indicate benefits of the use of He/O~2~ in routine treatment; however, the studies were small and exhibited methodological flaws.

Rodrigo et al.^([@r7])^ performed a systematic review with a meta-analysis of randomized clinical trials comparing the efficacy of He/O~2~ and oxygen for driving beta2 agonist nebulization in patients with acute asthma. The primary outcomes were change in spirometric parameters and severity scores; the secondary outcomes were hospital admission rate and severe adverse effects. The patients who received He/O~2~ presented a statistically significant improvement of the peak expiratory flow of 20L/m (95% confidence interval - 95%CI: 5.2 - 29.4; p = 0.005), which was more evident in the subgroup of patients with severe and very severe asthma).

He/O~2~ also produced significant decreases in the hospital admission rate (odds ratio - OR 0.49; 95% CI: 0.31 - 0.79; p = 0.003). The groups did not differ in the occurrence of serious adverse effects. Therefore, it may be concluded that the benefits of He/O~2~ on airflow limitation associated with airway obstruction as well as on hospital admission rate are clinically significant.

Few reports in the literature describe the use of He/O~2~ in patients subjected to mechanical ventilation, and most consist of retrospective studies and case reports; no controlled studies have been conducted with intubated patients.^([@r1])^

Our ventilation protocol for patients with severe obstructive disease was based on controlled hypoventilation; volume-controlled ventilation with high inspiratory output (approximately 60L/min) was combined with controlled hypoventilation (low respiratory rate: 8 - 10 cycles per minute (cpm) when the patient tolerated a pH of 7.25-7.28), a positive end-expiratory pressure (PEEP) of 0 to optimize the expiratory time, and limitation of the plateau pressure (Pplateau) to 30cmH~2~O ([Figure 2](#f2){ref-type="fig"}).

Figure 2Parameters and ventilatory mechanics before heliox administration. Controlled hypoventilation protocol.

As the present study was a case report, informed consent was waived by the local ethics committee.

CASE REPORTS
============

Clinical case 1
---------------

The case of a male, 39-year-old patient with history of bronchial asthma since childhood, irregular treatment (budesonide and terbutaline), and without outpatient monitoring is described. The patient had an episode of status asthmaticus requiring invasive mechanical ventilation approximately 10 years earlier.

The patient was brought to the emergency department due to dyspnea and wheezing that began 24 hours earlier and did not improve after short-acting bronchodilator therapy with salbutamol. Upon admission, the patient was in state of respiratory exhaustion; he was subjected to orotracheal intubation and connected to a ventilator, and bronchodilator therapy was started. Clinical, laboratory, and radiological assessments did not detect evidence of infection.

Due to the need for ventilatory support, the patient was transferred to the intensive care unit (ICU), where bronchodilator therapy and sedoanalgesia were optimized with administration of midazolam, alfentanil, and ketamine. Curarization was performed with vecuronium, and a controlled hypoventilation protocol was started. In terms of ventilatory mechanics, the patient exhibited increased expiratory time, severe bronchospasm, and a marked expiratory flow limitation pattern (time constant (τ), 1.69 seconds). In addition to the hypoventilation strategy, continuous high-dose inhaled and intravenous corticosteroid therapy (methylprednisolone) and magnesium sulfate were added to the nebulized bronchodilator therapy. Because his IgE levels were high, omalizumab was also administered.

On the 9^th^ day of admission, the patient still exhibited global respiratory failure, with severe acidemia and persistent expiratory flow limitation (peak inspiratory pressure (Ppeak), 57cmH~2~O; Pplateau, 25cmH~2~O; static compliance (Cs), 45mL/cmH~2~O; τ, 3.55 seconds; intrinsic PEEP (PEEPi), 1).

Ventilation with He/O~2~ was started (and maintained for three days), which produced significant improvement of the airway resistance and obstructive pattern, as shown by reduction of the peak pressure, resistance, τ, and PEEPi ([Table 1](#t1){ref-type="table"}).

###### 

Ventilation, blood gases, and ventilatory dynamics parameters during the hospital stay

  **Admission day**        **Clinical case 1**   **Clinical case 2**                                                                                                                     
  ------------------------ --------------------- --------------------- ------- ------- ------- ------- ------ ------ ------ ------- ------- ------- ------- ------- ------ ------ ------ ------
  Ventilator parameters                                                                                                                                                                  
    Modality               VC                    VC                    VC      VC      VC      VC      PS     SV     SV     VC      VC      PC      VC      PC      PS     SV     SV     SV
    FiO~2~                 100                   55                    60      60      40      50      50     60     40     40      45      65      30      50      40     60     28     28
    Frequency              12                    10                    10      10      10      12                           15      12      14      12      16                            
    Inspiratory pressure                                                                               10                                   19              20      10                    
    PEEPe                  0                     0                     0       0       0       0       4                    5       5       0       0       0       4                     
    Tidal volume           300                   370                   480     480     410     500                          420     400             370                                   
    I:E ratio              1:4                   1:6.7                 1:6.7   1:6.7   1:6.7   1:5.0                        1:2.0   1:2.0   1:4.0   1:5.0   1:3.0                         
  Ventilatory mechanics                                                                                                                                                                  
    Pplateau               23                    22                    13      19      25      10                           21      20      25      20      15                            
    Ppeak                                        58                    58      60      57      28                           46      44      50      48      24                            
    Cs                     21                    21                    28      37      45      50                           28      31      27      31      45                            
    Resistance                                   80                    68      82      80      24                           43      60      155     140     30                            
    τ                      3.79                  1.69                  1.9     3.03    3.55    1.2                          1.19    1.86    4.18    4.34    1.34    0.6                   
    PEEPi                  9                     4                     3       6       1       0                            1       1       5       5       1       0                     
  Arterial blood gases                                                                                                                                                                   
    pH                     7.29                  7.08                  7.37    7.22    7.34    7.44    7.48   7.46   7.47   7.3     7.43    7.43    7.35    7.44    7.48   7.51   7.46   7.45
    PaCO~2~                53.9                  112                   73.5    108     77.1    49.4    32.1   33.2   32.9   47      38.5    48.5    58.9    52      43.5   36.7   44.7   47.6
    PaO~2~                 493                   104                   112     125     139     126     76.2   112    107    165     100     273     97.7    80      144    87.7   135    148
    HCO~3~                 23.1                  11.2                  37.6    35.4    36.1    29.1    25.2   24.6   24.6   21.5    24.6    24.5    29.5    33.9    32     30.4   31.2   33.4
    BE                     -0.2                  2.2                   15.3    14.8    14.3    5.7     0.3    -0.2   -0.2   -3      0.1     0.6     6.5     10      8      6.3    7.6    9
    SaO~2~                 99.1                  97.1                  98.5    98.1    96.6    98.6    96.3   97.5   97.7   99.1    98      99.2    98.1    97      98.9   98.5   99.4   99.4
    Lactate                4                     0.5                   1.3     0.4     0.4     1.3     1.5    0.7    0.8    2.3     3.3     1.1     1.3     0.7     1.3    3.3    1.4    1.1

VC - volume-controlled ventilation; PS - pressure support ventilation; SV - spontaneous ventilation; PC - pressure-controlled ventilation; FiO~2~ - fraction of inspired oxygen; PEEPe - extrinsic positive end-expiratory pressure; I:E - inspiration:expiration; Pplateau - plateau pressure; Ppeak - peak inspiratory pressure; Cs - static compliance; τ - time constant; PEEPi - intrinsic positive end-expiratory pressure; PaCO~2~ - partial pressure of carbon dioxide; PaO~2~ - partial pressure of oxygen; HCO~3~ - bicarbonate; BE - base excess; SaO~2~ - arterial oxygen saturation.

On the 11^th^ day, progressive and consistent improvement of the blood gases was observed, curarization was discontinued, and sedation was decreased. On the 16^th^ day, the patient was weaned from the ventilator and extubated without any complications. The patient was free from hospital-acquired infections during his stay at the hospital, and thus, no antibiotic therapy was required.

The patient exhibited gradual clinical improvement without fever, was stable with regard to ventilation and hemodynamic parameters, and maintained adequate blood gases with an oxygen supply of 5L/min via a nasal cannula ([Table 1](#t1){ref-type="table"}).

On the 19^th^ day, because he no longer required intensive care, the patient was transferred to a hospital near his place of residence.

Hospital discharge occurred on the 30^th^ day.

Clinical case 2
---------------

The case of a female, 53-year-old patient with a history of bronchial asthma, followed-up at a pneumology service since the age of 30, is described. The patient had several hospital admissions for decompensated asthma (requiring ventilatory support on two occasions) and one episode of seizures related to decompensated asthma. She was regularly treated with budesonide, formoterol, montelukast, omeprazole, hydroxyzine, and home oxygen therapy (2L/min).

The patient was transported to the emergency department for dyspnea starting 36 hours earlier and progressed into respiratory arrest, resulting in orotracheal intubation and mechanical ventilation.

Due to her state of status asthmaticus/respiratory failure, she was transferred to the ICU, where her condition improved during the first 48 hours and was stable with regard to hemodynamic and ventilation parameters. Extubation was attempted, but it was complicated by immediate occurrence of severe bronchospasm.

On the 5^th^ day, the patient exhibited an episode of severe hypoxia, requiring an increase in sedation, curarization, and adjustment of bronchodilators. Regarding her ventilatory parameters, she exhibited marked expiratory flow limitation (Cs, 27mL/cmH~2~O; τ, 4.18 seconds; PEEPi, 5) due to severe bronchospasm.

The controlled hypoventilation protocol was restarted and combined with He/O~2~ (for four days) and inhaled intravenous corticosteroid therapy using methylprednisolone and montelukast (10mg/day).

The parameters of ventilatory dynamics exhibited significant improvement, namely reduction of the Pplateau, resistance, τ, and PEEPi ([Table 1](#t1){ref-type="table"}).

Weaning from mechanical ventilation was complicated by episodes of bronchospasm; eventually she was extubated on the 18^th^ day. The patient was free from hospital-acquired infections and was not subjected to antibiotic therapy.

At the time of transfer (20^th^ day), the patient was awake, calm, and cooperative, with efficient cough and preserved swallowing reflex, in addition to liquid respiratory secretions. The blood gases were adequate, with an oxygen supply of 2L/min through a nasal cannula, and she was capable of standing in a chair.

Hospital discharge occurred on the 40^th^ day.

DISCUSSION
==========

Many of the recently published studies on the use of He/O~2~ for refractory asthma have concluded that such treatments aim to reduce airflow resistance in obstructed airways, with consequent improvement of alveolar ventilation and of the efficacy of bronchodilator therapy by increasing the diffusion of drugs so that they might reach the smaller airways.^([@r5],[@r7],[@r9],[@r10])^

Currently, He/O~2~ has been mainly used in both pediatric and adult patients as adjuvant treatment while waiting for the onset of effects of conventional pharmacological treatments.^([@r5],[@r6])^ In the two clinical cases described here, we observed improvement of airway resistance to flow as well as the alveolar ventilation (demonstrated in the tables by progressive reduction of Ppeak, resistance, τ, and PEEPi). Thus, we believe that He/O~2~ might represent an option for refractory upper airway obstruction treatment in patients exhibiting progressive aggravation despite optimized ventilatory strategies and pharmacological treatment.

The use of He/O~2~ in mechanically ventilated patients has only been described in the literature in retrospective studies and case reports; no controlled studies of intubated patients have been reported to date.

Thus, recognizing the limitations of the present study, we consider the performance of controlled randomized studies essential to assess the identified benefits of He/O~2~ in adult patients subjected to invasive mechanical ventilation.

CONCLUSION
==========

Heliox is still sporadically used, and its true efficacy has not been well demonstrated. It appears to be an appropriate gas for oxygen and pharmacological treatment delivery, in respiratory diseases, due to its characteristic low density. It can be used simultaneously with conventional treatment for serious and refractory exacerbations of severe obstructive disease.

The level of evidence currently available does not allow a formal recommendation of heliox use in the intensive care unit; however, further clinical studies are required.
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